Skip to main content

CCTG Connection



Published:
Category: Publications
Publications: General Review
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis
 
Immune checkpoint inhibitors (ICI) have become an important treatment option for cancer patients and has been associated with improved survival outcomes across various tumor types. Cannabinoids are active components of cannabis and include tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabis use has increased in Canadian cancer patients and is often used for symptom management.
Read More

Published:
Category: Trials
Trial closure: IND232

IND.232, a Phase II Study of Durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer, has permanently closed.

Read More

Published:
Category: Trials
Closed to accrual: MAC27

MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.

Read More



Published:
Category: Group updates
Dr. Rebecca Wong Princess Margaret Cancer Centre

We are honoured to announce that the 2025 Joseph Pater Founder’s Award for Excellence in Clinical Trials Research has been presented to Dr. Rebecca Wong Princess Margaret Cancer Centre for her many years of trial and committee leadership with the group.She was Chair of CCTG’s Symptom Control (now Supportive Care) Committee from 2001-2018, and Esophageal disease-oriented group from 2009-2018.  She is currently a member of CCTG’s Clinical Trials Committee.

Read More

Published:
Category: Group updates
IND.244  CHU de Québec –  Hôpital L’Enfant-Jésus

The Investigational New Drug Program Team Award was presented to the IND.244 team at CHU de Québec – Hôpital L’Enfant-Jésus for their work activating and recruiting patients to this trial. Awarded at the CCTG Spring Meeting to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in a CCTG IND clinical trial to acknowledge their efforts and dedication to the success of clinical trials. 

Read More

Published:
Category: Group updates
Dr. Rachel Glicksman Princess Margaret Cancer Centre

The Ralph Meyer Phase III Program Young Investigator Award has been awarded to Dr. Rachel Glicksman from Princess Margaret Cancer Centre recognizing her active participation and enrollment activities as a young investigation in CCTG trials. This award is presented to individuals who have made significant contributions to the phase III program research projects.

Read More

Published:
Category: Group updates
ALC.7 Team Arthur J.E. Child Comprehensive Cancer Centre
At the 2025 annual Spring Meeting of Participants the group presented the Phase III Program Team Award for an intergroup led trial to the ALC.7 team from Arthur J.E.
Read More

Published:
Category: Group updates
Judy Needham, Chair Emeritus, Patient Representative Committee

It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year. 

Read More